Clinical Trial Update: "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" [Phase 3]

View source ↗

Summary

This entry describes a Phase 3 clinical trial evaluating CYB003, a deuterated psilocin analog, for Major Depressive Disorder, which is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• CYB003 (deuterated psilocin analog)

Snippet

Sponsor: Cybin IRL Limited | Conditions: Major Depressive Disorder | Phase 3 | Status: RECRUITING